alpha-aminopyridine has been researched along with Glomerulonephritis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhangal, G; Chawanasuntorapoj, R; Cook, HT; Masuda, ES; McDaid, JP; Pusey, CD; Smith, J; Tam, FW | 1 |
| Kapoor, S | 1 |
2 other study(ies) available for alpha-aminopyridine and Glomerulonephritis
| Article | Year |
|---|---|
A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis.
Topics: Aminopyridines; Animals; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Glomerulonephritis; Interleukin-1beta; Intracellular Signaling Peptides and Proteins; Macrophages; Mesangial Cells; Morpholines; Oxazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Rats; Rats, Inbred WKY; Severity of Illness Index; Signal Transduction; Syk Kinase | 2010 |
Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Topics: Aminopyridines; Autoimmune Diseases; Diabetes Mellitus, Type 2; Glomerulonephritis; Humans; Intracellular Signaling Peptides and Proteins; Morpholines; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Reperfusion Injury; Signal Transduction; Spleen; Syk Kinase | 2011 |